Amphastar Pharma

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amphastar Pharma excels in Q4 with strong revenue growth and product success

Amphastar Pharma's Q4 2022 performance reflects strong revenue growth, profitability, and product success, positioning the company well for future growth.
The company's focus on high-margin products, FDA approvals, and strategic investments in marketing and R&D underscore its commitment to innovation and market competitiveness.
While facing challenges in sustaining growth and managing costs, Amphastar Pharma has opportunities for expansion through product development, market penetration, and strategic initiatives.

Amphastar Pharma excels in Q1 2023, eyes growth opportunities

Amphastar Pharma's Q1 2023 showcased robust financial performance, driven by revenue growth and strategic product initiatives.
While facing challenges in market dynamics and margin management, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial strength, Amphastar Pharma demonstrates resilience and potential for sustained success.

Amphastar Pharma excels in Q2 with revenue growth and innovation

Amphastar Pharma's Q2 2023 performance reflects strong revenue growth, improved profitability, and operational efficiency, underpinned by robust sales across key products.
While facing challenges such as FDA approval delays and pipeline setbacks, the company's strategic focus on proprietary products and innovation presents opportunities for sustained growth.
By capitalizing on market demand, enhancing margins, and advancing its product pipeline, Amphastar is poised to navigate challenges and capitalize on opportunities for long-term success.

Amphastar Pharma excels in Q3 with robust revenue growth

Amphastar Pharma delivered impressive financial results in Q3 2023, marked by significant revenue growth and profitability improvements.
While facing challenges in sustaining rapid sales growth and managing debt obligations, the company's strategic focus on product expansion and market presence presents growth opportunities.
Overall, Amphastar Pharma's strong performance, diverse product portfolio, and financial stability position it well for future growth and value creation for stakeholders.

Amphastar Pharma excels in Q4 2023, eyes growth opportunities

Amphastar Pharma's Q4 2023 performance reflects robust growth in revenues, profit, and net income, driven by strategic focus and product demand.
While facing challenges like lower gross margins and capacity expansions, the company is poised for growth through innovation and market opportunities.
Opportunities lie in R&D advancements, product launches, and financial strength, positioning Amphastar Pharma for continued success and expansion.

Amphastar Pharma excels in Q1 2024, eyes growth through innovation

Amphastar Pharma's Q1 2024 showcases strong financial performance and strategic focus on product innovation and market expansion. While facing challenges in pricing and regulatory landscape, the company is poised for growth through new product launches and market penetration strategies.

Amphastar Pharma reports revenue growth amidst margin challenges and regulatory hurdles

Amphastar Pharma's Q3 performance showed revenue growth driven by key products.
While facing challenges in net income and margins, the company aims for sustainable growth.
Opportunities lie in product launches, market expansion, and regulatory progress.
Overall, Amphastar Pharma navigates financial challenges with strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2022. Second Quarter Highlights Net revenues of $123.5 million for the second quarter GAAP net income of $17.3 million, or $0.33 per share, for the second quarter Adjusted non-GAAP net income of $20.7 million, or $0.39 per share, for the second quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We've maintained momentum through the first half of 2022.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022

Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopressin, which have a TAM of $850 million, AMPH could nearly double its revenue by YE 2023 with proper execution.

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022

Amphastar Pharmaceutcls is near a buy zone with earnings due on or around Aug. 9. The post Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings appeared first on Investor's Business Daily.

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings

Amphastar Pharmaceutcls is near a buy zone with earnings due on or around Aug. 9. The post Stocks To Watch Ahead Of Earnings: Amphastar Pharmaceutcls appeared first on Investor's Business Daily.

Stocks To Watch Ahead Of Earnings: Amphastar Pharmaceutcls

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. In December 2021, the Company had received FDA tentative approval for the ANDA.

Amphastar Receives FDA Approval for Vasopressin

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled Syringe. Regadenoson is indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

Amphastar Receives FDA Approval for Regadenoson

Amphastar Pharmaceuticals has several key growth drivers: a strong pipeline of products currently awaiting approval, exciting products with growing sales, and growing marketing and distribution channels. With approvals for its developed products pending, AMPH could anticipate doubling its revenues if it can obtain those approvals on time.

Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio

Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?

Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dan Dischner - VP, Corporate Communications Bill Peters - CFO Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Tim Chiang - Northland Securities Operator Greetings, and welcome to the Amphastar Pharmaceuticals Incorporated First Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q1 2022 Results - Earnings Call Transcript

Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2022. First Quarter Highlights Net revenues of $120.4 million for the first quarter GAAP net income of $24.3 million, or $0.47 per share, for the first quarter Adjusted non-GAAP net income of $24.6 million, or $0.47 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "The first quarter continued where 2021 ended, with strong sales of our recently launched products, which confirms our strategy focused on complex products with commercial strength.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022

Amphastar Pharmaceuticals (AMPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Amphastar Pharmaceuticals (AMPH) This Earnings Season?

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after the market closes on Monday, May 9th 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Amphastar (AMPH) Keep the Earnings Surprise Streak Alive?

AbbVie

AmerisourceBergen

Archer-Daniels-Midland Company

CF Industries Holdings

Chevron

Hershey

Kroger

McKesson

The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.

10 Stocks That Have Moved Over 20% Since The Indices Lost Over 12%!

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

Amphastar Receives FDA Approval for Ganirelix Acetate Injection

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P.

Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

Palo Alto Networks

Even in a tough market, one large-cap company and a small-cap rising star are beating the odds.

These 2 Nasdaq Stocks Hit All-Time Highs Wednesday

Black Stone Minerals LP

CONSOL Energy

Commercial Metals

Matson

Sociedad Quimica Y Minera De Chile

Cactus

It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating.

7 “A”-Rated Stocks to Ground Your Portfolio

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q4 2021 Earnings Call Transcript

Amphastar (AMPH) delivered earnings and revenue surprises of 10.53% and 8.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Tops Q4 Earnings and Revenue Estimates

Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2021. Fourth Quarter Highlights Net revenues of $120.9 million for the fourth quarter GAAP net income of $19.8 million, or $0.39 per share, for the fourth quarter Adjusted non-GAAP net income of $20.8 million, or $0.42 per share, for the fourth quarter Full-Year Highlights Net revenues of $437.8 million for the fiscal year GAAP net income of $62.1 million, or $1.25 per share, for the fiscal year Adjusted non-GAAP net income of $68.0 million, or $1.37 per share, for the fiscal year Dr. Jack Zhang, Amphastar's President and Chief Executive Officer commented: "Last year was a turning point for Amphastar - with financial strength driven by the continued growth of our higher-margin products.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021, after the market closes on Thursday, March 10th, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

News for Amphastar Pharma Stock (AMPH)